A Phase 1/2 interventional study of TSN1611 and TSN1611 in Malignant Neoplasm, sponsored by Tyligand Pharmaceuticals (Suzhou) Limited. Recruiting at 24 sites in 2 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-11-16.
Sponsored by Tyligand Pharmaceuticals (Suzhou) Limited · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The study is a first-in-human (FIH), open-label, multi-center phase 1/2 study of TSN1611 in subjects with KRAS G12D mutant advanced solid tumors. This study will consist of a phase 1a dose escalation/confirmation part, phase 1b dose randomization part and phase 2 dose expansion parts of TSN1611 as monotherapy or in combination with other anti-cancer therapies. This study will evaluate the efficacy of TSN1611 at RP2D(s) through ORR using RECIST version 1.1, and determine and confirm the MTD/RP2D for TSN1611 in combination with cetuximab, in combination with cetuximab and mFOLFOX6, in combination with cetuximab and FOLFIRI, in combination with gemcitabine and albumin-bound paclitaxel in subjects with selected solid tumors.
Phase 1 Part of TSN1611 Monotherapy:
The phase 1 part will evaluate the prespecified dose levels of TSN1611. Dose escalation will continue until up to the highest planned dose or the maximum tolerated dose (MTD) or recommended phase 2 dose (RP2D) is determined. Dose optimization could be performed as indicated by the emerging data.
Phase 2 Part of TSN1611 Monotherapy:
phase 2 part of TSN1611 monotherapy will evaluate the efficacy and safety of TSN1611 as monotherapy at the RP2D until disease progression or unacceptable toxicity in separate groups of patients with pancreatic cancer, colorectal cancer, non-small cell lung cancer, or other solid tumors, harboring KRAS G12D mutations.
Phase 1b/2 Part of TSN1611 Combination Therapy:
This part will consist of the investigations of 4 combined therapies (Cohort A, B ,C and D). In each cohort, there will be a Phase 1b Safety Lead-in Stage to determine the dose of TSN1611 for the combination therapy (this part will be conducted in selected sites), followed by the Phase 2 Expansion Stage to enroll more subjects to determine the efficacy in different cohorts.
10,838 studies on the registry are indexed under Neoplasms; 2,322 are open to participants now.
This study's planned enrollment of 570 is above the median of 60 across 7,716 interventional studies indexed under Neoplasms.
Browse Neoplasms studies →This is the only study on the registry with Tyligand Pharmaceuticals (Suzhou) Limited as lead sponsor.
Counted across the registry records on this site, refreshed daily.
The criteria were revised on the registry on Nov 16, 2026. See what changed
Subjects must meet all the following inclusion criteria to be eligible for participation in this study:
Subjects with or cytologically confirmed locally advanced or solid tumor harboring KRAS G12D mutation; subjects must be or intolerable to standard treatment, or have no standard treatment available, or the subject is ineligible or declines standard treatment.
Phase 2 part of TSN1611 Monotherapy:
Subjects with histologically or cytologically confirmed locally advanced or metastatic PDAC、CRC and NSCLC harboring KRAS G12D mutation; According to the requirements of different combined cohorts, the number of previous treatments is taken into account.
Phase 1b/2 Part of TSN1611 in Combination Therapies:
Subjects with histologically or cytologically confirmed locally advanced or metastatic PDAC、CRC and NSCLC harboring KRAS G12D mutation; According to the requirements of different combined cohorts, the number of previous treatments is taken into account.
Exclusion Criteria
Subjects will be excluded if they meet any of the following criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.
Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Leptomeningeal disease
Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.
Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The phase 1 part will evaluate the prespecified sequential dose levels of TSN1611 in subjects with KRAS G12D mutant advanced solid tumors to determine the recommended dose of TSN1611 for further investigation.
Drug: TSN1611
Phase 2 part will evaluate the efficacy and safety of TSN1611 as monotherapy at the recommended dose level in separate groups of patients with pancreatic cancer, colorectal cancer, non-small cell lung cancer, or other solid tumors, harboring KRAS G12D mutations.
Drug: TSN1611
Cohort A: TSN1611 combined with cetuximab treating subjects with advanced solid tumors harboring KRAS G12D mutation:
Drug: TSN1611
Cohort B: TSN1611 combined with GnP regimen (i.e., gemcitabine and nab-paclitaxel) treating subjects with advanced PDAC with KRAS G12D mutation who received no prior systemic treatment in the advanced setting.
Drug: TSN1611
Cohort C: TSN1611 combined with cetuximab and mFOLFOX6 regimen (i.e., fluorouracil, leucovorin, oxaliplatin) treating subjects with advanced CRC with KRAS G12D mutation who received no prior systemic treatment in the advanced setting.
Drug: TSN1611
Cohort D: TSN1611 combined with cetuximab and FOLFIRI regimen (i.e., fluorouracil, leucovorin, irinotecan) treating participants with advanced CRC with KRAS G12D mutation who received no prior systemic treatment in the advanced setting. When the enrollment is active for both Cohort C and Cohort D simultaneously, participants could be allocated to either cohort alternatively (e.g., through randomization method), unless contradicted to either cohort.
Drug: TSN1611
The phase 1b part will evaluate the prespecified sequential dose levels of TSN1611 in subjects with KRAS G12D mutant advanced solid tumors to determine the recommended dose of TSN1611 for further investigation.
Drug: TSN1611
TSN1611 will be administered at the assigned dose level, orally, until disease progression or intolerable toxicity.
TSN1611 at the assigned dose level, orally, BID, combined with cetuximab, IV, every 2 weeks (Q2W), continuously in 28-day cycles
TSN1611 at the assigned dose level, orally, BID, combined with GnP regimen (gemcitabine and nab-paclitaxel), IV, on Day 1, 8 and 15, continuously in 28-day cycles
Also known as: Paclitaxel (albumin-bound)
TSN1611 BID everyday and Patients will be administered with mFOLFOX6 on Days 1 and 2, every 2 weeks.
Also known as: Oxaliplatin injection, fluorouracil, leucovorin
TSN1611 at the assigned dose level, orally, BID, combined with cetuximab and FOLFIRI (irinotecan, leucovorin, and fluorouracil), IV, every 2 weeks (Q2W), continuously in 28-day cycles,
Also known as: irinotecan, leucovorin, fluorouracil
Dose limiting toxicities (DLTs) in phase 1 part
To determine the maximum tolerated dose (MTD) and/or recommended phase 2 dose(s) (RP2D\[s\]) of TSN1611 as monotherapy in subjects with KRAS G12D mutant advanced solid tumors.
Time frame: 21 days
Objective response rate (ORR) in phase 2 part
To evaluate the anti-tumor activity of TSN1611 using Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1.
Time frame: Up to 3 years
Dose limiting toxicities (DLTs) in phase 1b part of TSN1611 Combination Therapy
Phase 1b: To determine and confirm the MTD/RP2D for TSN1611 in combination with cetuximab, in combination with cetuximab and mFOLFOX6, in combination with cetuximab and FOLFIRI, in combination with gemcitabine and albumin-bound paclitaxel in participants with selected solid tumors.
Time frame: 28 days
Objective response rate (ORR) in phase 2 part of TSN1611 Combination Therapy
Phase 2: To evaluate the efficacy of TSN1611 in combination with cetuximab, in combination with cetuximab and mFOLFOX6, in combination with cetuximab and FOLFIRI, in combination with gemcitabine and albumin-bound paclitaxel through ORR using RECIST version 1.1.
Time frame: Up to 3 years
Adverse events
To assess the safety profile and tolerability of TSN1611 as monotherapy in subjects with KRAS G12D mutant advanced solid tumors.
Time frame: Up to 3 years
Area under the plasma concentration-time curve (AUC)
To characterize the pharmacokinetic (PK) profile of TSN1611.
Time frame: 9 weeks
Maximum blood concentrations (Cmax)
To characterize the PK profile of TSN1611.
Time frame: 9 weeks
Time to maximum blood concentration (Tmax)
To characterize the PK profile of TSN1611.
Time frame: 9 weeks
Duration of response (DOR)
To evaluate the anti-tumor activity of TSN1611 using RECIST version 1.1.
Time frame: Up to 3 years
Time to response (TTR)
To evaluate the anti-tumor activity of TSN1611 using RECIST version 1.1.
Time frame: Up to 3 years
Disease control rate (DCR)
To evaluate the anti-tumor activity of TSN1611 using RECIST version 1.1.
Time frame: Up to 3 years
Progression free survival (PFS)
To evaluate the anti-tumor activity of TSN1611 using RECIST version 1.1.
Time frame: Up to 3 years
Overall survival
Time frame: Up to 3 years
Plan to share: No
No publications or documents are linked to this record.
Started Apr 2024 (actual). Primary completion is estimated for Oct 2027, 42 months after the start.
Of 197 industry-sponsored phase 1/2 interventional studies under Neoplasms, half reached primary completion within 61 months of starting (the median), counting those still running; a quarter within 41 and three quarters within 88. This study's planned 42 months is below that.
Counting every sponsor, half of 299 studies reached it within 61 months; a quarter within 40 and three quarters within 89.
Neoplasms covers many different conditions, not one, so the studies compared here vary widely. Read these figures as a rough guide.
Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 16, 2026: primary completion Oct 2026 → Oct 2027 and completion Apr 2027 → Apr 2028.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.